Egrifta (eh-GRIF-tuh, tesamorelin), the first drug to treat abdominal fat deposits caused by HIV meds

February 2011

You'll hear about Egrifta (eh-GRIF-tuh, tesamorelin), the first drug to treat abdominal fat deposits caused by HIV meds.

This lipodystrophy can be distressing to patients...decrease adherence to HIV meds...and might increase cardiovascular risk.

Egrifta is a human growth hormone releasing factor that's injected subcutaneously once daily.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote